In vitro susceptibility of Aspergillus fumigatus to isavuconazole: Correlation with itraconazole, voriconazole, and posaconazole

Lea Gregson; Joanne Goodwin; Adam Johnson; Laura McEntee; Caroline B. Moore; Malcolm Richardson; William W. Hope; Susan J. Howard

doi:10.1128/AAC.01141-13

In vitro susceptibility of Aspergillus fumigatus to isavuconazole: Correlation with itraconazole, voriconazole, and posaconazole

Lea Gregson, Joanne Goodwin, Adam Johnson, Laura McEntee, Caroline B. Moore, Malcolm Richardson, William W. Hope, Susan J. Howard

Research output: Contribution to journal › Article › peer-review

Abstract

Triazoles are first-line agents for treating aspergillosis. The prevalence of azole resistance in Aspergillus fumigatus is increasing, and cross-resistance is a growing concern. In this study, the susceptibilities of 40 A. fumigatus clinical isolates were tested by using the CLSI method with amphotericin B, itraconazole, voriconazole, posaconazole, and the new triazole isavuconazole. Isavuconazole MICs were higher in strains with reduced susceptibilities to other triazoles, mirroring changes in voriconazole susceptibility. Isavuconazole MICs differed depending on the Cyp51A substitution. Copyright © 2013, American Society for Microbiology.

Original language	English
Pages (from-to)	5778-5780
Number of pages	2
Journal	Antimicrobial Agents and Chemotherapy
Volume	57
Issue number	11
DOIs	https://doi.org/10.1128/AAC.01141-13
Publication status	Published - Nov 2013

Access to Document

10.1128/AAC.01141-13

http://aac.asm.org/content/57/11/5778.full.pdf+html

Cite this

@article{2b0fbfe0a8314314a2e09a80358a4b84,

title = "In vitro susceptibility of Aspergillus fumigatus to isavuconazole: Correlation with itraconazole, voriconazole, and posaconazole",

abstract = "Triazoles are first-line agents for treating aspergillosis. The prevalence of azole resistance in Aspergillus fumigatus is increasing, and cross-resistance is a growing concern. In this study, the susceptibilities of 40 A. fumigatus clinical isolates were tested by using the CLSI method with amphotericin B, itraconazole, voriconazole, posaconazole, and the new triazole isavuconazole. Isavuconazole MICs were higher in strains with reduced susceptibilities to other triazoles, mirroring changes in voriconazole susceptibility. Isavuconazole MICs differed depending on the Cyp51A substitution. Copyright {\textcopyright} 2013, American Society for Microbiology.",

author = "Lea Gregson and Joanne Goodwin and Adam Johnson and Laura McEntee and Moore, {Caroline B.} and Malcolm Richardson and Hope, {William W.} and Howard, {Susan J.}",

year = "2013",

month = nov,

doi = "10.1128/AAC.01141-13",

language = "English",

volume = "57",

pages = "5778--5780",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "11",

}

TY - JOUR

T1 - In vitro susceptibility of Aspergillus fumigatus to isavuconazole: Correlation with itraconazole, voriconazole, and posaconazole

AU - Gregson, Lea

AU - Goodwin, Joanne

AU - Johnson, Adam

AU - McEntee, Laura

AU - Moore, Caroline B.

AU - Richardson, Malcolm

AU - Hope, William W.

AU - Howard, Susan J.

PY - 2013/11

Y1 - 2013/11

N2 - Triazoles are first-line agents for treating aspergillosis. The prevalence of azole resistance in Aspergillus fumigatus is increasing, and cross-resistance is a growing concern. In this study, the susceptibilities of 40 A. fumigatus clinical isolates were tested by using the CLSI method with amphotericin B, itraconazole, voriconazole, posaconazole, and the new triazole isavuconazole. Isavuconazole MICs were higher in strains with reduced susceptibilities to other triazoles, mirroring changes in voriconazole susceptibility. Isavuconazole MICs differed depending on the Cyp51A substitution. Copyright © 2013, American Society for Microbiology.

AB - Triazoles are first-line agents for treating aspergillosis. The prevalence of azole resistance in Aspergillus fumigatus is increasing, and cross-resistance is a growing concern. In this study, the susceptibilities of 40 A. fumigatus clinical isolates were tested by using the CLSI method with amphotericin B, itraconazole, voriconazole, posaconazole, and the new triazole isavuconazole. Isavuconazole MICs were higher in strains with reduced susceptibilities to other triazoles, mirroring changes in voriconazole susceptibility. Isavuconazole MICs differed depending on the Cyp51A substitution. Copyright © 2013, American Society for Microbiology.

U2 - 10.1128/AAC.01141-13

DO - 10.1128/AAC.01141-13

M3 - Article

SN - 0066-4804

VL - 57

SP - 5778

EP - 5780

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 11

ER -

In vitro susceptibility of Aspergillus fumigatus to isavuconazole: Correlation with itraconazole, voriconazole, and posaconazole

Abstract

Access to Document

Fingerprint

Cite this